•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced the launch of a new sub-brand, RenBiologics, to represent its antibody discovery business division. The RenBiologics business will focus on out-licensing and co-development of the company’s extensive library of fully human antibodies, as well as licensing of…